dc.contributor.author |
Walsh, Jacinta |
|
dc.contributor.author |
Griffin, Brendan T. |
|
dc.contributor.author |
Clarke, Gerard |
|
dc.contributor.author |
Hyland, Niall P. |
|
dc.date.accessioned |
2018-06-05T08:55:13Z |
|
dc.date.available |
2018-06-05T08:55:13Z |
|
dc.date.issued |
2018-05-21 |
|
dc.identifier.citation |
Walsh, J., Griffin, B. T., Clarke, G. and Hyland, N. P. (2018) 'Drug-gut microbiota interactions: implications for neuropharmacology', British Journal of Pharmacology. doi:10.1111/bph.14366 |
en |
dc.identifier.issn |
0007-1188 |
|
dc.identifier.issn |
1476-5381 |
|
dc.identifier.uri |
http://hdl.handle.net/10468/6243 |
|
dc.identifier.doi |
10.1111/bph.14366 |
|
dc.description.abstract |
The fate and activity of drugs are frequently dictated not only by the host per se but also by the microorganisms present in the gastrointestinal tract. The gut microbiome is known to, both directly and indirectly, affect drug metabolism. More evidence now hints at the impact that drugs can have on the function and composition of the gut microbiome. Both microbiota-mediated alterations in drug metabolism and drug-mediated alterations in the gut microbiome can have beneficial or detrimental effects on the host. Greater insights into the mechanisms driving these reciprocal drug-gut microbiota interactions are needed, to guide the development of microbiome-targeted dietary or pharmacological interventions, with the potential to enhance drug efficacy or reduce drug side-effects. In this review, we explore the relationship between drugs and the gut microbiome, with a specific focus on potential mechanisms underpinning the drug-mediated alterations on the gut microbiome and the potential implications for psychoactive drugs. |
en |
dc.format.mimetype |
application/pdf |
en |
dc.language.iso |
en |
en |
dc.publisher |
John Wiley & Sons, Inc. on behalf of the British Pharmacological Society |
en |
dc.rights |
© 2018, British Pharmacological Society. All rights reserved. Published by John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Walsh, J., Griffin, B. T., Clarke, G. and Hyland, N. P. (2018) 'Drug-gut microbiota interactions: implications for neuropharmacology', British Journal of Pharmacology. doi:10.1111/bph.14366, which has been published in final form at https://doi.org/10.1111/bph.14366. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
en |
dc.subject |
Drug metabolism |
en |
dc.subject |
Neuropharmacology |
en |
dc.subject |
Microbial enzymes |
en |
dc.subject |
Drug |
en |
dc.subject |
Microbiome |
en |
dc.title |
Drug-gut microbiota interactions: implications for neuropharmacology |
en |
dc.type |
Article (peer-reviewed) |
en |
dc.internal.authorcontactother |
Brendan Griffin, School Of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: brendan.griffin@ucc.ie |
en |
dc.internal.availability |
Full text available |
en |
dc.check.info |
Access to this article is restricted until 12 months after publication by request of the publisher. |
en |
dc.check.date |
2019-05-21 |
|
dc.date.updated |
2018-05-30T09:05:27Z |
|
dc.description.version |
Accepted Version |
en |
dc.internal.rssid |
439639285 |
|
dc.contributor.funder |
Science Foundation Ireland
|
en |
dc.description.status |
Peer reviewed |
en |
dc.identifier.journaltitle |
British Journal of Pharmacology |
en |
dc.internal.copyrightchecked |
Yes |
en |
dc.internal.licenseacceptance |
Yes |
en |
dc.internal.IRISemailaddress |
brendan.griffin@ucc.ie |
en |
dc.internal.IRISemailaddress |
n.hyland@ucc.ie |
en |
dc.internal.bibliocheck |
In press. Check for vol. / issue / page numbers. Amend citation as necessary. |
|
dc.relation.project |
info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/
|
en |